NCT04176952TerminatedPhase 2
PRIMUS002: An Umbrella Phase II Study Examining Two Neo-adjuvant Regimens (FOLFOX-A and AG) in Resectable and Borderline Resectable Pancreatic Ductal AdenoCarcinoma (PDAC), Focusing on Biomarker and Liquid Biopsy Development
Judith Dixon-Hughes3 sites in 1 country31 target enrollmentStarted: March 5, 2019Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Terminated
- Sponsor
- Enrollment
- 31
- Locations
- 3
- Primary Endpoint
- Time to progression post FOLFOX-A induction treatment
Study Overview
Brief Summary
PRIMUS 002 is looking at 2 different chemotherapy regimens in the neo-adjuvant setting for pancreatic cancer. Each treatment will be given for 3 months prior to surgery
Detailed Description
This is an integrated, open label, non-randomised, phase II trial of 2 neo-adjuvant regimens (FOLFOX-A and AG) assessing efficacy and toxicity with integrated translational work. The study is powered on testing a proposed DNA damage response deficient biomarker for responsiveness in patients treated with FOLFOX-A; patients being treated with AG are recruited concurrently. The study has a prospective safety assessment of neo-adjuvant chemotherapy and neo-adjuvant chemotherapy followed by chemoradiotherapy consisting of conventional radiotherapy with concomitant capecitabine. This safety assessment will include all patients (FOLFOX-A and AG)
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 16 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patient has been enrolled in the Precision-Panc Master Protocol and their tissue has been deemed suitable for Next Generation Sequencing analysis (a Precision-Panc Master Protocol identifier will be required at the time of study enrolment)
- •Signed informed consent given for PRIMUS 002 study
- •Age ≥ 16 years
- •Resectable or borderline resectable pancreatic cancer as defined by National Comprehensive Cancer Network criteria following discussion at the Multi Disciplinary Team
- •Measurable Disease as per RECIST 1.1
- •Histological or cytologically proven pancreatic ductal adenocarcinoma (including variants)
- •Able to undergo biliary drainage using a covered or partially covered self-expanding metal stent if jaundiced
- •Eastern Cooperative Oncology Group performance status 0 and 1
- •Adequate liver/bone marrow function as defined by:
- •Neutrophils (ANC) ≥ 1.5 x 109/l
- •Platelets ≥ 100 x 109/l
- •Haemoglobin ≥ 9.0g/dL
- •White Blood Cells (WBC) ≥ 3 x 109/l
- •Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) unless bilirubin rise is due to Gilbert's syndrome
- •Aspartate transaminase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN (or <5 x ULN in the presence of liver metastases)
- •Estimated creatinine clearance ≥ 60 mL/min (as calculated by Cockcroft and Gault or Wright formula or measured by EDTA clearance)
- •Negative serum Human Chorionic Gonadotropin (HCG) test for females with child bearing potential. Postmenopausal women must have been amenorrhoeic for at least 12 months to be considered of non-childbearing potential
- •Woman of child bearing potential, and men with female partners of child bearing potential, must agree to use adequate contraceptive measures (see section 7.1.11.1) for the duration of the study and for up to 6 months after the completion of study treatment.
- •Able to comply with protocol requirements and deemed fit for surgical resection, chemotherapy and CRT
Exclusion Criteria
- •Distant metastatic disease
- •History of previous or concurrent malignancy diagnosis (except curatively treated basal cell carcinoma of skin or carcinoma in situ of cervix) in the last 3 years
- •Prior chemotherapy or CRT for pancreatic cancer
- •Known hypersensitivity for any component of any study drug
- •Active infection including Herpes Zoster and chickenpox
- •Uncontrolled congestive heart failure (CHF), or history of myocardial ischemia (MI), unstable angina, stroke, or transient ischemia within previous 6 months.
- •Serious medical or psychological condition precluding neo-adjuvant treatment and surgical resection
- •New York Heart Association Classification Grade III or IV
- •Liver cirrhosis (except for Child-Pugh A)
- •Major surgery within 28 days prior to trial entry
- •Any patients receiving treatment with brivudin, sorivudin and analogues or patients who have not stopped these drugs at least 4 weeks prior to the start of study treatment
- •Any patient with severe diarrhoea (defined as ≥grade 3 diarrhoea despite maximum supportive measures and exclusion of underlying infection)
- •Patients with known malabsorption
- •Patients with known or suspected dihydropyrimidine dehydrogenase (DPD) deficiency
- •Grade ≥ 2 peripheral neuropathy
- •Administration of any investigational drug within 28 days or 5 half-lives, whichever is longer, prior to receiving the first dose of trial treatment
Arms & Interventions
FOLFOX-A
Experimental
FOLFOX A arm (14-day cycle)
- nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first).
- Oxaliplatin: 85mg/m2, IV over 2 hours, day 1.
- Folinic acid: 350mg flat dose, IV over 2 hours, day 1.
- Fluorouracil infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours or 48 hours as per local practice.)
Patients will also receive daily G-CSF as primary prophylaxis against neutropenic events for all cycles. This should be given as per local policy for chemotherapy regimens given every 14 days e.g. it may be started on day 4 for 7 days (preparation and dose should be given as per local policy).
Intervention: FOLFOX-A (Drug)
Abraxane and Gemcitabine
Active Comparator
Nab-Paclitaxel + Gemcitabine (AG) arm (28-day cycle)
- nab-paclitaxel: 125mg/m2 IV over 30 minutes on days 1, 8 and 15 (administered first).
- Gemcitabine 1000mg/m2 IV over 30 minutes on days 1, 8 and 15 (immediately following nab-paclitaxel).
Intervention: AG (Drug)
Outcomes
Primary Outcomes
Time to progression post FOLFOX-A induction treatment
Time Frame: CT scans will take place at baseline, pre chemoradiotherapy and pre surgery, over approximately 6 months
date of progression after FOLFOX-A neo-adjuvant chemotherapy as assessed by RECIST 1.1
Secondary Outcomes
- Response post neo-adjuvant chemotherapy(CT scan will be performed at baseline and then post neo-adjuvant chemotherapy (approximately 3 months later))
- R0 rate post surgery(Post surgery which will be approximately 4 months post registration)
- Safety and tolerability of study drugs: NCI CTCAE 4.03(Assessed at every clinic visit during treatment, for approximately 3 months post registration)
- Quality of life assessed by EORTC QLQ-PAN26(Quality of life will be assessed from registration until study is completed at various timepoints until patient death. Each patient will be followed up for at least 24 months post registration)
- Proving liquid biopsies can be used to define patient subgroups(From date of registration to date of surgery. On average 4 months after registration)
- College of American Pathologists tumour regression grade(Post surgery which will be approximately 4 months post registration)
- Safety and tolerability of chemoradiotherapy: NCI CTCAE 4.03(Assessed at every chemoradiotherapy visit and pre-surgery (once Chemoradiotherapy added). Chemoradiotherapy will take place 5 days a week for three weeks)
- Surgical complication rate(Assessed post surgery, approximately 4 months post registration)
- Overall survival(From date of registration until date of death assessed for up to 5 years post registration)
- Disease free survival(from date of registration until date of disease recurrence assessed for at least 24 months post registration)
- Neurotoxicity(Neurotoxicity will be assessed from registration until study is completed at various timepoints until patient death. Each patient will be followed up for at least 24 months post registration)
- Health Economics(Health economics will be assessed from registration until study is completed at various timepoints until patient death. Each patient will be followed up for at least 24 months post registration)
- Quality of life assessed by EORTC QLQ-C30(Quality of life will be assessed from registration until study is completed at various timepoints until patient death. Each patient will be followed up for at least 24 months post registration)
Investigators
Judith Dixon-Hughes
Project Manager
University of Glasgow
Study Sites (3)
Loading locations...
Similar Trials
Terminated
Phase 2
Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic CancerBorderline Resectable Pancreatic CancerNCT02241551Nathan Bahary, MD2
Completed
Not Applicable
Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal AdenocarcinomaGastric CancerNCT05540145Cancer Institute and Hospital, Chinese Academy of Medical Sciences70
Terminated
Phase 2
A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in TaiwanResected Pancreatic CancerAdjuvant ChemotherapyPancreatic CancerNCT04070313TTY Biopharm36
Unknown
Phase 1
Trial of Neoadjuvant Short Course IMRT Followed by Surgery and IORT for Resectable Pancreatic CancerPancreatic NeoplasmsNCT01372735University Hospital Heidelberg46
Unknown
Phase 2
Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in Locally Advanced Non-small Cell Lung CancerNon-small Cell Lung CancerNCT01054482The First Affiliated Hospital of Guangzhou Medical University120